{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000013","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.882761+00:00","generated_at":"2026-06-04T05:32:05.601714+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"AEON Biopharma reports FY 2023 results; aligns with FDA on Phase 3 migraine design","bullets":["End-of-Phase 2 meeting with FDA achieved alignment on pivotal Phase 3 trial design for episodic and chronic migraine.","Phase 2 chronic migraine study completed enrollment (492 patients); interim analysis data expected Q2 2024.","Announced $15M private placement of senior secured convertible notes with Daewoong; first $5M closed, second $10M due April 2024.","Cash runway projected through June 2024 only; company to fund late-stage clinical development.","No financial results provided in press release beyond qualitative business update."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000013","json":"https://secwatch.observer/filing/0001837607-24-000013.json","markdown":"https://secwatch.observer/filing/0001837607-24-000013.md","text":"https://secwatch.observer/filing/0001837607-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/0001837607-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/aeon-20240329x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:32:05.601714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2726ff1b3314191bb2cb0eb2523fe0f45a244bf","claim":"AEON Biopharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/0001837607-24-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}